{"id":"hydrochloride-carliprazine-capsules","safety":{"commonSideEffects":[{"rate":null,"effect":"Akathisia"},{"rate":null,"effect":"Extrapyramidal symptoms"},{"rate":null,"effect":"Weight gain"},{"rate":null,"effect":"Sedation"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Headache"}]},"_chembl":{"chemblId":"CHEMBL1200628","moleculeType":"Small molecule","molecularWeight":"1485.73"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Carliprazine modulates dopaminergic and serotonergic neurotransmission by binding to dopamine D2 and D3 receptors as a partial agonist, which helps normalize dopamine signaling in psychotic and mood disorders. It also acts as a partial agonist at serotonin 5-HT1A receptors, contributing to its anxiolytic and mood-stabilizing properties. This multi-target mechanism distinguishes it from first-generation antipsychotics and some other atypical agents.","oneSentence":"Carliprazine is an atypical antipsychotic that acts as a dopamine D2/D3 receptor partial agonist and serotonin 5-HT1A receptor partial agonist.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:41:57.094Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Schizophrenia"},{"name":"Bipolar disorder (acute mania/mixed episodes)"},{"name":"Major depressive disorder (adjunctive treatment)"}]},"trialDetails":[{"nctId":"NCT06589817","phase":"PHASE3","title":"A Double-Blind, Randomized Comparative Study of Carliprazine and Aripiprazole in Patients with Acute Schizophrenia","status":"NOT_YET_RECRUITING","sponsor":"Chengdu Kanghong Pharmaceutical Group Co., Ltd.","startDate":"2024-10","conditions":"Acute Schizophrenia","enrollment":376}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Hydrochloride Carliprazine capsules","genericName":"Hydrochloride Carliprazine capsules","companyName":"Chengdu Kanghong Pharmaceutical Group Co., Ltd.","companyId":"chengdu-kanghong-pharmaceutical-group-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Carliprazine is an atypical antipsychotic that acts as a dopamine D2/D3 receptor partial agonist and serotonin 5-HT1A receptor partial agonist. Used for Schizophrenia, Bipolar disorder (acute mania/mixed episodes), Major depressive disorder (adjunctive treatment).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}